Atai stocks.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.

Atai stocks. Things To Know About Atai stocks.

On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the ...Open Int (30-Day): The average total open interest for all option contracts (across all expiration dates) for the last 30 days. Atai Life Sciences N.V. stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.Nov 17, 2023 · The upgrade of atai Life Sciences N.V. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ... Oct 24, 2023 · Mind Medicine Inc. ( MNMD) MindMed shares are down by 38.7% over the past three months, but they are up 23.2% year to date as of Oct. 24. The New York-based company specializes in the development ...

ATAI stock closed at $1.76 and is up $0.10 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. ATAI has a strong overall score of 70 meaning the stock holds a better value than 70% of stocks at its current price.

Validation of atai's operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021 Strong cash position of approx. $273M (as of December 31 st , 2022) and access to up to an additional $160m from term loan facility with Hercules 2 lead to ...

Get the latest Atai Life Sciences N.V. (ATAI) stock news and headlines to help you in your trading and investing decisions.APD Vs ATAI: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. ... We currently support US stocks and STOXX Europe 600 stocks. How it Works Plans & Pricing Help Center My Portfolios.WebOct 2, 2023 · 3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Insider Trading.

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,105.36% from the …

Dec 1, 2023 · View atai Life Sciences NV ATAI investment & stock information. Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Nov 29, 2021 · Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. The stock immediately popped 40% but it has since halved in value and Atai's current market cap ... With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.0. These 7 analysts have an average price target of $13.29 versus the current price of ATAI Life Sciences at $1.3447, implying upside. Below is a summary of how these 7 analysts rated ATAI Life ...NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. September 14, 2023. Press Release.WebThis influential firm issued a $20 share price target for ATAI, propelling its stock value to surge. As of May 24, 2023, ATAI Life Sciences boasts an average one-year price target of $13.75, as ...

Can ATAI Life Sciences N.V. (NASDAQ: ATAI) Still Be Considered A Loss When It’s Down -57.89% YTD? Marketing Sentinel about 20 hours ago ATAI Life Sciences NV Reports Qâ â â ¦â â Financial Results and Pipeline Progress GuruFocus 16 days ago Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026 …WebThe ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks Dividend yield The ratio of annual dividend to current …ATAI Signals & Forecast. There are mixed signals in the stock today. The ATA Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more …APD Vs ATAI: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. ... We currently support US stocks and STOXX Europe 600 stocks. How it Works Plans & Pricing Help Center My Portfolios.WebIn May 2021, Atai purchased additional preferred stock of Neuronasal. As of the date, the company now holds a 56.5% equity ownership position in Neuronasal – a company focused on treating concussions and other forms of …

Stock Price Forecast The 6 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 11.00, with a high estimate of 21.00 and a low estimate of 5.10.

Apr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Atai Life Sciences (ATAI 7.69%) is approaching psychedelic therapy development from the perspective of a venture capital investor. Each program in its pipeline is managed by a separate company ...When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.ATAI Life Sciences N.V. Common Shares (ATAI) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the price... So far this year, Atai has tumbled more than 40% and Compass Pathways has fallen almost 60%. The Horizons Psychedelic Stock Index ETF, which tracks the North American Psychedelics Index , is down ...Over the past 12 months, ATAI’s stock has witnessed a remarkable growth rate of 631.38%. Despite its impressive performance in the stock market, ATAI has faced its fair share of challenges since ...

ATAI Life Sciences N.V. () Stock Market info Recommendations: Buy or sell ATAI Life Sciences N.V. stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the ATAI Life Sciences N.V. share forecasts, stock quote and buy / sell signals below.According to present data ATAI Life Sciences N.V.'s ATAI shares and potentially …

Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …

Key Stock Data · P/E Ratio (TTM). N/A · EPS (TTM). $-0.42 · Market Cap. $185.93 M · Shares Outstanding. 166.01 M · Public Float. 114.08 M · Yield. ATAI is not ...One example is the crashing of Atai Life Sciences (Nasdaq: ATAI) stock in January because of bad results from a Phase 2a proof-of-concept trial assessing the safety, tolerability, and efficacy of a single IV administration of ketamine. Shares of Atai’s stock crashed nearly 40% to an all-time low when the trial results were announced on Jan. 6.Webatai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ... is selling $2 billion of stock in Las Vegas Sands Corp. so the ...Complete ATAI Life Sciences N.V. stock information by Barron's. View real-time ATAI stock price and news, along with industry-best analysis.The upgrade of atai Life Sciences N.V. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...Atai already has an MDMA-derived drug in its pipeline, EMP-01, in collaboration with Empath Bio. If the FDA approves MDMA, it will help Atai as it will further interest and investments into the ...Open Int (30-Day): The average total open interest for all option contracts (across all expiration dates) for the last 30 days. Atai Life Sciences N.V. stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.Atai Life Sciences (ATAI 7.69%) is approaching psychedelic therapy development from the perspective of a venture capital investor. Each program in its pipeline is managed by a separate company ...The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors. 7 Stocks That AI Predicts Will Soar in 2024 InvestorPlace. Artificial intelligence (AI) has become an invaluable ...May 25, 2023 · This influential firm issued a $20 share price target for ATAI, propelling its stock value to surge. As of May 24, 2023, ATAI Life Sciences boasts an average one-year price target of $13.75, as ...

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.ATAI Life Sciences. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01 ... Feb 9, 2023 · 1. ATAI Life Sciences. The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (NASDAQ: ATAI) stock. This 12-month price target implies an upside ... Instagram:https://instagram. fscfxpre market moversaks and neiman marcususaa pet The comedown has also put a dent in Angermayer’s wealth. Adjusting for its cash, investors now value Atai’s drug pipeline at $470 million. Nearly $1.8 billion was raised by psychedelics ...Web carlyle captrustatrfx The Atai Life Sciences N.V. stock forecast for tomorrow is $ 1.055893, which would represent a -2.23% loss compared to the current price. In the next week, the price of ATAI is expected to decrease by -18.90% and hit $ 0.875911. As far as the long-term Atai Life Sciences N.V. stock forecast is ... dental discount plan vs insurance May 25, 2023 · Over the past 12 months, ATAI’s stock has witnessed a remarkable growth rate of 631.38%. Despite its impressive performance in the stock market, ATAI has faced its fair share of challenges since ... Atai Life Sciences has a strong financial position with $227.5 million in cash and funding to support its operations into the 1st half of 2026. The global schizophrenia drug market is expected to ...